 | • レポートコード：D0GIR-02233 • 出版社/出版日：GlobalInfoResearch / 2020年9月23日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、121ページ • 納品方法：Eメール • 産業分類：医療、製薬、バイオ |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、腫瘍学治療薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。腫瘍学治療薬の種類別市場規模（化学療法、標的療法、免疫療法（生物学的療法）、ホルモン療法、その他）、用途別市場規模（血液がん、乳がん、消化器がん、前立腺がん、呼吸器・肺がん、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Roche、Pfizer、Bristol-Myers Squibb、Celgene、AstraZeneca、Novartis、Eli Lilly、Merck & Co.、Johnson & Johnson、Amgen、Sanofi、Teva、AbbVie、Eisai、Bayer、Ipsen、Takeda、Otsuka、Biogen Idec、Astellas、Merck KGaA、Gilead Sciences ・地域別グローバル市場分析 2015年-2020年 ・腫瘍学治療薬の北米市場（アメリカ、カナダ、メキシコ） ・腫瘍学治療薬のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・腫瘍学治療薬のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・腫瘍学治療薬の南米市場（ブラジル、アルゼンチン） ・腫瘍学治療薬の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：化学療法、標的療法、免疫療法（生物学的療法）、ホルモン療法、その他 ・用途別分析：血液がん、乳がん、消化器がん、前立腺がん、呼吸器・肺がん、その他 ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論 |
Market Overview
The Drugs for Oncology market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
The most likely (base case) scenario is that the global Drugs for Oncology sales will be xx in 2020 from Drugs for Oncology million in 2019, with a change xx% between 2019 and 2020. In addition, based on the latest study, it is to predict that the Covid-19 will be under control in key countries like the United States, Western Europe, East Asia, by the end of Q2 (June), and will resume normal production in Q3 and Q4, the global Drugs for Oncology market size is expected to grow at xx% or more annually for the next five years.
This report also researches and evaluates the impact of Covid-19 outbreak on the Drugs for Oncology industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Drugs for Oncology and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).
Market segmentation
Drugs for Oncology market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Drugs for Oncology market has been segmented into:
Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Others
By Application, Drugs for Oncology has been segmented into:
Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Respiratory/Lung Cancer
Others
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Drugs for Oncology market presented in the report. This section sheds light on the sales growth of different regional and country-level Drugs for Oncology markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Drugs for Oncology market.
The report offers in-depth assessment of the growth and other aspects of the Drugs for Oncology market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Drugs for Oncology Market Share Analysis
Drugs for Oncology competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Drugs for Oncology sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Drugs for Oncology sales, revenue and market share for each player covered in this report.
The major players covered in Drugs for Oncology are:
Roche
Pfizer
Bristol-Myers Squibb
Celgene
AstraZeneca
Novartis
Eli Lilly
Merck & Co.
Johnson & Johnson
Amgen
Sanofi
Teva
AbbVie
Eisai
Bayer
Ipsen
Takeda
Otsuka
Biogen Idec
Astellas
Merck KGaA
Gilead Sciences
Among other players domestic and global, Drugs for Oncology market share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
1 Drugs for Oncology Market Overview
1.1 Product Overview and Scope of Drugs for Oncology
1.2 Classification of Drugs for Oncology by Type
1.2.1 Global Drugs for Oncology Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Drugs for Oncology Revenue Market Share by Type in 2019
1.2.3 Chemotherapy
1.2.4 Targeted Therapy
1.2.5 Immunotherapy (Biologic Therapy)
1.2.6 Hormonal Therapy
1.2.7 Others
1.3 Global Drugs for Oncology Market by Application
1.3.1 Overview: Global Drugs for Oncology Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Blood Cancer
1.3.3 Breast Cancer
1.3.4 Gastrointestinal Cancer
1.3.5 Prostate Cancer
1.3.6 Respiratory/Lung Cancer
1.3.7 Others
1.4 Global Drugs for Oncology Market by Regions
1.4.1 Global Drugs for Oncology Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Drugs for Oncology (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Drugs for Oncology Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Drugs for Oncology Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Drugs for Oncology Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Drugs for Oncology Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Drugs for Oncology Status and Prospect (2015-2025)
1.5 COVID-19 Outbreak: Drugs for Oncology Industry Impact
1.5.1 COVID-19 Potential Implications for the Drugs for Oncology
1.5.1.1 Scenario One: Very Optimistic: COVID-19 has No Influence on Drugs for Oncology
1.5.1.2 Scenario Two: Optimistic: COVID-19 Will Be Under Control by the End of April
1.5.1.3 Scenario Three: Gloomy: COVID-19 Will Be Under Control Between Q3 and Q4
1.5.1.4 Scenario Four: Most Likely: COVID-19 Will Be Under Control by the End of Q2
1.5.2 Opportunity Analysis in Covid-19 Crisis
1.5.3 Market Risk and Restraints
1.5.4 Market Driving Force
2 Company Profiles
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Roche SWOT Analysis
2.1.4 Roche Product and Services
2.1.5 Roche Drugs for Oncology Revenue, Gross Margin and Market Share (2018-2019)
2.2 Pfizer
2.2.1 Pfizer Details
2.2.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Pfizer SWOT Analysis
2.2.4 Pfizer Product and Services
2.2.5 Pfizer Drugs for Oncology Revenue, Gross Margin and Market Share (2018-2019)
2.3 Bristol-Myers Squibb
2.3.1 Bristol-Myers Squibb Details
2.3.2 Bristol-Myers Squibb Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Bristol-Myers Squibb SWOT Analysis
2.3.4 Bristol-Myers Squibb Product and Services
2.3.5 Bristol-Myers Squibb Drugs for Oncology Revenue, Gross Margin and Market Share (2018-2019)
2.4 Celgene
2.4.1 Celgene Details
2.4.2 Celgene Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Celgene SWOT Analysis
2.4.4 Celgene Product and Services
2.4.5 Celgene Drugs for Oncology Revenue, Gross Margin and Market Share (2018-2019)
2.5 AstraZeneca
2.5.1 AstraZeneca Details
2.5.2 AstraZeneca Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 AstraZeneca SWOT Analysis
2.5.4 AstraZeneca Product and Services
2.5.5 AstraZeneca Drugs for Oncology Revenue, Gross Margin and Market Share (2018-2019)
2.6 Novartis
2.6.1 Novartis Details
2.6.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Novartis Product and Services
2.6.4 Novartis Drugs for Oncology Revenue, Gross Margin and Market Share (2018-2019)
2.7 Eli Lilly
2.7.1 Eli Lilly Details
2.7.2 Eli Lilly Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Eli Lilly Product and Services
2.7.4 Eli Lilly Drugs for Oncology Revenue, Gross Margin and Market Share (2018-2019)
2.8 Merck & Co.
2.8.1 Merck & Co. Details
2.8.2 Merck & Co. Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Merck & Co. Product and Services
2.8.4 Merck & Co. Drugs for Oncology Revenue, Gross Margin and Market Share (2018-2019)
2.9 Johnson & Johnson
2.9.1 Johnson & Johnson Details
2.9.2 Johnson & Johnson Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Johnson & Johnson Product and Services
2.9.4 Johnson & Johnson Drugs for Oncology Revenue, Gross Margin and Market Share (2018-2019)
2.10 Amgen
2.10.1 Amgen Details
2.10.2 Amgen Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Amgen Product and Services
2.10.4 Amgen Drugs for Oncology Revenue, Gross Margin and Market Share (2018-2019)
2.11 Sanofi
2.11.1 Sanofi Details
2.11.2 Sanofi Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Sanofi Product and Services
2.11.4 Sanofi Drugs for Oncology Revenue, Gross Margin and Market Share (2018-2019)
2.12 Teva
2.12.1 Teva Details
2.12.2 Teva Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Teva Product and Services
2.12.4 Teva Drugs for Oncology Revenue, Gross Margin and Market Share (2018-2019)
2.13 AbbVie
2.13.1 AbbVie Details
2.13.2 AbbVie Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 AbbVie Product and Services
2.13.4 AbbVie Drugs for Oncology Revenue, Gross Margin and Market Share (2018-2019)
2.14 Eisai
2.14.1 Eisai Details
2.14.2 Eisai Major Business and Total Revenue (Financial Highlights) Analysis
2.14.3 Eisai Product and Services
2.14.4 Eisai Drugs for Oncology Revenue, Gross Margin and Market Share (2018-2019)
2.15 Bayer
2.15.1 Bayer Details
2.15.2 Bayer Major Business and Total Revenue (Financial Highlights) Analysis
2.15.3 Bayer Product and Services
2.15.4 Bayer Drugs for Oncology Revenue, Gross Margin and Market Share (2018-2019)
2.16 Ipsen
2.16.1 Ipsen Details
2.16.2 Ipsen Major Business and Total Revenue (Financial Highlights) Analysis
2.16.3 Ipsen Product and Services
2.16.4 Ipsen Drugs for Oncology Revenue, Gross Margin and Market Share (2018-2019)
2.17 Takeda
2.17.1 Takeda Details
2.17.2 Takeda Major Business and Total Revenue (Financial Highlights) Analysis
2.17.3 Takeda Product and Services
2.17.4 Takeda Drugs for Oncology Revenue, Gross Margin and Market Share (2018-2019)
2.18 Otsuka
2.18.1 Otsuka Details
2.18.2 Otsuka Major Business and Total Revenue (Financial Highlights) Analysis
2.18.3 Otsuka Product and Services
2.18.3 Otsuka Drugs for Oncology Revenue, Gross Margin and Market Share (2018-2019)
2.19 Biogen Idec
2.19.1 Biogen Idec Details
2.19.2 Biogen Idec Major Business and Total Revenue (Financial Highlights) Analysis
2.19.3 Biogen Idec Product and Services
2.19.4 Biogen Idec Drugs for Oncology Revenue, Gross Margin and Market Share (2018-2019)
2.20 Astellas
2.20.1 Astellas Details
2.20.2 Astellas Major Business and Total Revenue (Financial Highlights) Analysis
2.20.3 Astellas Product and Services
2.20.4 Astellas Drugs for Oncology Revenue, Gross Margin and Market Share (2018-2019)
2.21 Merck KGaA
2.21.1 Merck KGaA Details
2.21.2 Merck KGaA Major Business and Total Revenue (Financial Highlights) Analysis
2.21.3 Merck KGaA Product and Services
2.21.4 Merck KGaA Drugs for Oncology Revenue, Gross Margin and Market Share (2018-2019)
2.22 Gilead Sciences
2.22.1 Gilead Sciences Details
2.22.2 Gilead Sciences Major Business and Total Revenue (Financial Highlights) Analysis
2.22.3 Gilead Sciences Product and Services
2.22.4 Gilead Sciences Drugs for Oncology Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Drugs for Oncology Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Drugs for Oncology Players Market Share
3.2.2 Top 10 Drugs for Oncology Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Drugs for Oncology Revenue and Market Share by Regions
4.2 North America Drugs for Oncology Revenue and Growth Rate (2015-2020)
4.3 Europe Drugs for Oncology Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Drugs for Oncology Revenue and Growth Rate (2015-2020)
4.5 South America Drugs for Oncology Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Drugs for Oncology Revenue and Growth Rate (2015-2020)
5 North America Drugs for Oncology Revenue by Countries
5.1 North America Drugs for Oncology Revenue by Countries (2015-2020)
5.2 USA Drugs for Oncology Revenue and Growth Rate (2015-2020)
5.3 Canada Drugs for Oncology Revenue and Growth Rate (2015-2020)
5.4 Mexico Drugs for Oncology Revenue and Growth Rate (2015-2020)
6 Europe Drugs for Oncology Revenue by Countries
6.1 Europe Drugs for Oncology Revenue by Countries (2015-2020)
6.2 Germany Drugs for Oncology Revenue and Growth Rate (2015-2020)
6.3 UK Drugs for Oncology Revenue and Growth Rate (2015-2020)
6.4 France Drugs for Oncology Revenue and Growth Rate (2015-2020)
6.5 Russia Drugs for Oncology Revenue and Growth Rate (2015-2020)
6.6 Italy Drugs for Oncology Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Drugs for Oncology Revenue by Countries
7.1 Asia-Pacific Drugs for Oncology Revenue by Countries (2015-2020)
7.2 China Drugs for Oncology Revenue and Growth Rate (2015-2020)
7.3 Japan Drugs for Oncology Revenue and Growth Rate (2015-2020)
7.4 Korea Drugs for Oncology Revenue and Growth Rate (2015-2020)
7.5 India Drugs for Oncology Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Drugs for Oncology Revenue and Growth Rate (2015-2020)
8 South America Drugs for Oncology Revenue by Countries
8.1 South America Drugs for Oncology Revenue by Countries (2015-2020)
8.2 Brazil Drugs for Oncology Revenue and Growth Rate (2015-2020)
8.3 Argentina Drugs for Oncology Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Drugs for Oncology by Countries
9.1 Middle East & Africa Drugs for Oncology Revenue by Countries (2015-2020)
9.2 Saudi Arabia Drugs for Oncology Revenue and Growth Rate (2015-2020)
9.3 UAE Drugs for Oncology Revenue and Growth Rate (2015-2020)
9.4 Egypt Drugs for Oncology Revenue and Growth Rate (2015-2020)
9.5 South Africa Drugs for Oncology Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Drugs for Oncology Revenue and Market Share by Type (2015-2020)
10.2 Global Drugs for Oncology Market Forecast by Type (2019-2024)
10.3 Chemotherapy Revenue Growth Rate (2015-2025)
10.4 Targeted Therapy Revenue Growth Rate (2015-2025)
10.5 Immunotherapy (Biologic Therapy) Revenue Growth Rate (2015-2025)
10.6 Hormonal Therapy Revenue Growth Rate (2015-2025)
10.7 Others Revenue Growth Rate (2015-2025)
11 Global Drugs for Oncology Market Segment by Application
11.1 Global Drugs for Oncology Revenue Market Share by Application (2015-2020)
11.2 Drugs for Oncology Market Forecast by Application (2019-2024)
11.3 Blood Cancer Revenue Growth (2015-2020)
11.4 Breast Cancer Revenue Growth (2015-2020)
11.5 Gastrointestinal Cancer Revenue Growth (2015-2020)
11.6 Prostate Cancer Revenue Growth (2015-2020)
11.7 Respiratory/Lung Cancer Revenue Growth (2015-2020)
11.8 Others Revenue Growth (2015-2020)
12 Global Drugs for Oncology Market Size Forecast (2021-2025)
12.1 Global Drugs for Oncology Market Size Forecast (2021-2025)
12.2 Global Drugs for Oncology Market Forecast by Regions (2021-2025)
12.3 North America Drugs for Oncology Revenue Market Forecast (2021-2025)
12.4 Europe Drugs for Oncology Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Drugs for Oncology Revenue Market Forecast (2021-2025)
12.6 South America Drugs for Oncology Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Drugs for Oncology Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Drugs for Oncology Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Drugs for Oncology by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Drugs for Oncology Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Drugs for Oncology Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Global Drugs for Oncology Market Size and Growth Estimation in Various Scenarios in 2020
Table 6. Roche Corporate Information, Location and Competitors
Table 7. Roche Drugs for Oncology Major Business
Table 8. Roche Drugs for Oncology Total Revenue (USD Million) (2017-2018)
Table 9. Roche SWOT Analysis
Table 10. Roche Drugs for Oncology Product and Solutions
Table 11. Roche Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 12. Pfizer Corporate Information, Location and Competitors
Table 13. Pfizer Drugs for Oncology Major Business
Table 14. Pfizer Drugs for Oncology Total Revenue (USD Million) (2018-2019)
Table 15. Pfizer SWOT Analysis
Table 16. Pfizer Drugs for Oncology Product and Solutions
Table 17. Pfizer Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 18. Bristol-Myers Squibb Corporate Information, Location and Competitors
Table 19. Bristol-Myers Squibb Drugs for Oncology Major Business
Table 20. Bristol-Myers Squibb Drugs for Oncology Total Revenue (USD Million) (2017-2018)
Table 21. Bristol-Myers Squibb SWOT Analysis
Table 22. Bristol-Myers Squibb Drugs for Oncology Product and Solutions
Table 23. Bristol-Myers Squibb Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 24. Celgene Corporate Information, Location and Competitors
Table 25. Celgene Drugs for Oncology Major Business
Table 26. Celgene Drugs for Oncology Total Revenue (USD Million) (2017-2018)
Table 27. Celgene SWOT Analysis
Table 28. Celgene Drugs for Oncology Product and Solutions
Table 29. Celgene Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 30. AstraZeneca Corporate Information, Location and Competitors
Table 31. AstraZeneca Drugs for Oncology Major Business
Table 32. AstraZeneca Drugs for Oncology Total Revenue (USD Million) (2017-2018)
Table 33. AstraZeneca SWOT Analysis
Table 34. AstraZeneca Drugs for Oncology Product and Solutions
Table 35. AstraZeneca Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 36. Novartis Corporate Information, Location and Competitors
Table 37. Novartis Drugs for Oncology Major Business
Table 38. Novartis Drugs for Oncology Total Revenue (USD Million) (2017-2018)
Table 39. Novartis SWOT Analysis
Table 40. Novartis Drugs for Oncology Product and Solutions
Table 41. Novartis Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 42. Eli Lilly Corporate Information, Location and Competitors
Table 43. Eli Lilly Drugs for Oncology Major Business
Table 44. Eli Lilly Drugs for Oncology Total Revenue (USD Million) (2017-2018)
Table 45. Eli Lilly SWOT Analysis
Table 46. Eli Lilly Drugs for Oncology Product and Solutions
Table 47. Eli Lilly Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 48. Merck & Co. Corporate Information, Location and Competitors
Table 49. Merck & Co. Drugs for Oncology Major Business
Table 50. Merck & Co. Drugs for Oncology Total Revenue (USD Million) (2017-2018)
Table 51. Merck & Co. SWOT Analysis
Table 52. Merck & Co. Drugs for Oncology Product and Solutions
Table 53. Merck & Co. Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 54. Johnson & Johnson Corporate Information, Location and Competitors
Table 55. Johnson & Johnson Drugs for Oncology Major Business
Table 56. Johnson & Johnson Drugs for Oncology Total Revenue (USD Million) (2017-2018)
Table 57. Johnson & Johnson SWOT Analysis
Table 58. Johnson & Johnson Drugs for Oncology Product and Solutions
Table 59. Johnson & Johnson Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 60. Amgen Corporate Information, Location and Competitors
Table 61. Amgen Drugs for Oncology Major Business
Table 62. Amgen Drugs for Oncology Total Revenue (USD Million) (2017-2018)
Table 63. Amgen SWOT Analysis
Table 64. Amgen Drugs for Oncology Product and Solutions
Table 65. Amgen Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 66. Sanofi Corporate Information, Location and Competitors
Table 67. Sanofi Drugs for Oncology Major Business
Table 68. Sanofi Drugs for Oncology Total Revenue (USD Million) (2017-2018)
Table 69. Sanofi SWOT Analysis
Table 70. Sanofi Drugs for Oncology Product and Solutions
Table 71. Sanofi Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 72. Teva Corporate Information, Location and Competitors
Table 73. Teva Drugs for Oncology Major Business
Table 74. Teva Drugs for Oncology Total Revenue (USD Million) (2017-2018)
Table 75. Teva SWOT Analysis
Table 76. Teva Drugs for Oncology Product and Solutions
Table 77. Teva Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 78. AbbVie Corporate Information, Location and Competitors
Table 79. AbbVie Drugs for Oncology Major Business
Table 80. AbbVie Drugs for Oncology Total Revenue (USD Million) (2017-2018)
Table 81. AbbVie SWOT Analysis
Table 82. AbbVie Drugs for Oncology Product and Solutions
Table 83. AbbVie Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 84. Eisai Corporate Information, Location and Competitors
Table 85. Eisai Drugs for Oncology Major Business
Table 86. Eisai Drugs for Oncology Total Revenue (USD Million) (2017-2018)
Table 87. Eisai SWOT Analysis
Table 88. Eisai Drugs for Oncology Product and Solutions
Table 89. Eisai Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 90. Bayer Corporate Information, Location and Competitors
Table 91. Bayer Drugs for Oncology Major Business
Table 92. Bayer Drugs for Oncology Total Revenue (USD Million) (2017-2018)
Table 93. Bayer SWOT Analysis
Table 94. Bayer Drugs for Oncology Product and Solutions
Table 95. Bayer Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 96. Ipsen Corporate Information, Location and Competitors
Table 97. Ipsen Drugs for Oncology Major Business
Table 98. Ipsen Drugs for Oncology Total Revenue (USD Million) (2017-2018)
Table 99. Ipsen SWOT Analysis
Table 100. Ipsen Drugs for Oncology Product and Solutions
Table 101. Ipsen Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 102. Takeda Corporate Information, Location and Competitors
Table 103. Takeda Drugs for Oncology Major Business
Table 104. Takeda Drugs for Oncology Total Revenue (USD Million) (2017-2018)
Table 105. Takeda SWOT Analysis
Table 106. Takeda Drugs for Oncology Product and Solutions
Table 107. Takeda Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 108. Otsuka Drugs for Oncology Type and Application
Table 109. Otsuka Drugs for Oncology Major Business
Table 110. Otsuka Drugs for Oncology Total Revenue (USD Million) (2017-2018)
Table 111. Otsuka SWOT Analysis
Table 112. Otsuka Drugs for Oncology Product and Solutions
Table 113. Otsuka Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 114. Biogen Idec Corporate Information, Location and Competitors
Table 115. Biogen Idec Drugs for Oncology Major Business
Table 116. Biogen Idec Drugs for Oncology Total Revenue (USD Million) (2017-2018)
Table 117. Biogen Idec SWOT Analysis
Table 118. Biogen Idec Drugs for Oncology Product and Solutions
Table 119. Biogen Idec Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 120. Astellas Corporate Information, Location and Competitors
Table 121. Astellas Drugs for Oncology Major Business
Table 122. Astellas Drugs for Oncology Total Revenue (USD Million) (2017-2018)
Table 123. Astellas SWOT Analysis
Table 124. Astellas Drugs for Oncology Product and Solutions
Table 125. Astellas Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 126. Merck KGaA Corporate Information, Location and Competitors
Table 127. Merck KGaA Drugs for Oncology Major Business
Table 128. Merck KGaA Drugs for Oncology Total Revenue (USD Million) (2017-2018)
Table 129. Merck KGaA SWOT Analysis
Table 130. Merck KGaA Drugs for Oncology Product and Solutions
Table 131. Merck KGaA Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 132. Gilead Sciences Corporate Information, Location and Competitors
Table 133. Gilead Sciences Drugs for Oncology Major Business
Table 134. Gilead Sciences Drugs for Oncology Total Revenue (USD Million) (2017-2018)
Table 135. Gilead Sciences SWOT Analysis
Table 136. Gilead Sciences Drugs for Oncology Product and Solutions
Table 137. Gilead Sciences Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 138. Global Drugs for Oncology Revenue (Million USD) by Players (2015-2020)
Table 139. Global Drugs for Oncology Revenue Share by Players (2015-2020)
Table 140. Global Drugs for Oncology Revenue (Million USD) by Regions (2015-2020)
Table 141. Global Drugs for Oncology Revenue Market Share by Regions (2015-2020)
Table 142. North America Drugs for Oncology Revenue by Countries (2015-2020)
Table 143. North America Drugs for Oncology Revenue Market Share by Countries (2015-2020)
Table 144. Europe Drugs for Oncology Revenue (Million USD) by Countries (2015-2020)
Table 145. Asia-Pacific Drugs for Oncology Revenue (Million USD) by Countries (2015-2020)
Table 146. South America Drugs for Oncology Revenue by Countries (2015-2020)
Table 147. South America Drugs for Oncology Revenue Market Share by Countries (2015-2020)
Table 148. Middle East and Africa Drugs for Oncology Revenue (Million USD) by Countries (2015-2020)
Table 149. Middle East and Africa Drugs for Oncology Revenue Market Share by Countries (2015-2020)
Table 150. Global Drugs for Oncology Revenue (Million USD) by Type (2015-2020)
Table 151. Global Drugs for Oncology Revenue Share by Type (2015-2020)
Table 152. Global Drugs for Oncology Revenue Forecast by Type (2021-2025)
Table 153. Global Drugs for Oncology Revenue by Application (2015-2020)
Table 154. Global Drugs for Oncology Revenue Share by Application (2015-2020)
Table 155. Global Drugs for Oncology Revenue Forecast by Application (2021-2025)
Table 156. Global Drugs for Oncology Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Drugs for Oncology Picture
Figure 2. Global Drugs for Oncology Revenue Market Share by Type in 2019
Figure 3. Chemotherapy Picture
Figure 4. Targeted Therapy Picture
Figure 5. Immunotherapy (Biologic Therapy) Picture
Figure 6. Hormonal Therapy Picture
Figure 7. Others Picture
Figure 8. Drugs for Oncology Revenue Market Share by Application in 2019
Figure 9. Blood Cancer Picture
Figure 10. Breast Cancer Picture
Figure 11. Gastrointestinal Cancer Picture
Figure 12. Prostate Cancer Picture
Figure 13. Respiratory/Lung Cancer Picture
Figure 14. Others Picture
Figure 15. Global Drugs for Oncology Revenue (USD Million) and Growth Rate (2015-2025)
Figure 16. North America Drugs for Oncology Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Europe Drugs for Oncology Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Asia-Pacific Drugs for Oncology Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. South America Drugs for Oncology Revenue (Million USD) and Growth Rate (2015-2025)
Figure 20. Middle East and Africa Drugs for Oncology Revenue (Million USD) and Growth Rate (2015-2025)
Figure 21. Global Drugs for Oncology Revenue (Million USD) and Growth Rate (2015-2025)
Figure 22. Global Drugs for Oncology Revenue Share by Players in 2019
Figure 23. Global Top 5 Players Drugs for Oncology Revenue Market Share in 2019
Figure 24. Global Top 10 Players Drugs for Oncology Revenue Market Share in 2019
Figure 25. Key Players Market Share Trend
Figure 26. Global Drugs for Oncology Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 27. Global Drugs for Oncology Revenue Market Share by Regions (2015-2020)
Figure 28. Global Drugs for Oncology Revenue Market Share by Regions in 2018
Figure 29. North America Drugs for Oncology Revenue and Growth Rate (2015-2020)
Figure 30. Europe Drugs for Oncology Revenue and Growth Rate (2015-2020)
Figure 31. Asia-Pacific Drugs for Oncology Revenue and Growth Rate (2015-2020)
Figure 32. South America Drugs for Oncology Revenue and Growth Rate (2015-2020)
Figure 33. Middle East and Africa Drugs for Oncology Revenue and Growth Rate (2015-2020)
Figure 34. North America Drugs for Oncology Revenue Market Share by Countries (2015-2020)
Figure 35. North America Drugs for Oncology Revenue Market Share by Countries in 2019
Figure 36. USA Drugs for Oncology Revenue and Growth Rate (2015-2020)
Figure 37. Canada Drugs for Oncology Revenue and Growth Rate (2015-2020)
Figure 38. Mexico Drugs for Oncology Revenue and Growth Rate (2015-2020)
Figure 39. Europe Drugs for Oncology Revenue Market Share by Countries (2015-2020)
Figure 40. Europe Drugs for Oncology Revenue Market Share by Countries in 2019
Figure 41. Germany Drugs for Oncology Revenue and Growth Rate (2015-2020)
Figure 42. UK Drugs for Oncology Revenue and Growth Rate (2015-2020)
Figure 43. France Drugs for Oncology Revenue and Growth Rate (2015-2020)
Figure 44. Russia Drugs for Oncology Revenue and Growth Rate (2015-2020)
Figure 45. Italy Drugs for Oncology Revenue and Growth Rate (2015-2020)
Figure 46. Asia-Pacific Drugs for Oncology Revenue Market Share by Countries (2015-2020)
Figure 47. Asia-Pacific Drugs for Oncology Revenue Market Share by Countries in 2019
Figure 48. China Drugs for Oncology Revenue and Growth Rate (2015-2020)
Figure 49. Japan Drugs for Oncology Revenue and Growth Rate (2015-2020)
Figure 50. Korea Drugs for Oncology Revenue and Growth Rate (2015-2020)
Figure 51. India Drugs for Oncology Revenue and Growth Rate (2015-2020)
Figure 52. Southeast Asia Drugs for Oncology Revenue and Growth Rate (2015-2020)
Figure 53. South America Drugs for Oncology Revenue Market Share by Countries (2015-2020)
Figure 54. South America Drugs for Oncology Revenue Market Share by Countries in 2019
Figure 55. Brazil Drugs for Oncology Revenue and Growth Rate (2015-2020)
Figure 56. Argentina Drugs for Oncology Revenue and Growth Rate (2015-2020)
Figure 57. Middle East and Africa Drugs for Oncology Revenue Market Share by Countries (2015-2020)
Figure 58. Middle East and Africa Drugs for Oncology Revenue Market Share by Countries in 2019
Figure 59. Saudi Arabia Drugs for Oncology Revenue and Growth Rate (2015-2020)
Figure 60. UAE Drugs for Oncology Revenue and Growth Rate (2015-2020)
Figure 61. Egypt Drugs for Oncology Revenue and Growth Rate (2015-2020)
Figure 62. South Africa Drugs for Oncology Revenue and Growth Rate (2015-2020)
Figure 63. Global Drugs for Oncology Revenue Share by Type (2015-2020)
Figure 64. Global Drugs for Oncology Revenue Share by Type in 2019
Figure 65. Global Drugs for Oncology Market Share Forecast by Type (2021-2025)
Figure 66. Global Chemotherapy Revenue Growth Rate (2015-2020)
Figure 67. Global Targeted Therapy Revenue Growth Rate (2015-2020)
Figure 68. Global Immunotherapy (Biologic Therapy) Revenue Growth Rate (2015-2020)
Figure 69. Global Hormonal Therapy Revenue Growth Rate (2015-2020)
Figure 70. Global Others Revenue Growth Rate (2015-2020)
Figure 71. Global Drugs for Oncology Revenue Share by Application (2015-2020)
Figure 72. Global Drugs for Oncology Revenue Share by Application in 2019
Figure 73. Global Drugs for Oncology Market Share Forecast by Application (2021-2025)
Figure 74. Global Blood Cancer Revenue Growth Rate (2015-2020)
Figure 75. Global Breast Cancer Revenue Growth Rate (2015-2020)
Figure 76. Global Gastrointestinal Cancer Revenue Growth Rate (2015-2020)
Figure 77. Global Prostate Cancer Revenue Growth Rate (2015-2020)
Figure 78. Global Respiratory/Lung Cancer Revenue Growth Rate (2015-2020)
Figure 79. Global Others Revenue Growth Rate (2015-2020)
Figure 80. Global Drugs for Oncology Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 81. Global Drugs for Oncology Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 82. Global Drugs for Oncology Revenue Market Share Forecast by Regions (2021-2025)
Figure 83. North America Drugs for Oncology Revenue Market Forecast (2021-2025)
Figure 84. Europe Drugs for Oncology Revenue Market Forecast (2021-2025)
Figure 85. Asia-Pacific Drugs for Oncology Revenue Market Forecast (2021-2025)
Figure 86. South America Drugs for Oncology Revenue Market Forecast (2021-2025)
Figure 87. Middle East and Africa Drugs for Oncology Revenue Market Forecast (2021-2025)
Figure 88. Sales Channel: Direct Channel vs Indirect Channel
獣医腫瘍の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The Veterinary Oncology market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, t…- 血液学適応症関連薬の世界市場2020年：メーカー別、地域別、種類・用途別 Market Overview The Hematology Indications Related Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chai…
- 泌尿生殖器薬の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Genitourinary Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Genitourinary Drugs marke…
- 頭頸部がん治療薬/治療剤の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Head and Neck Cancer Drugs/Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 4.0% in the forecast period of 2020 to 2025 and will expected to reach USD 1466.9 million by 2025, from USD 1255.8 million in 2019. …
- 眼瞼炎治療薬の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The Blepharitis Treatment Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimiz…